Last reviewed · How we verify
Belsomra
At a glance
| Generic name | Belsomra |
|---|---|
| Sponsor | National Institute on Drug Abuse (NIDA) |
| Target | Orexin receptor type 1, Orexin receptor type 2, Orexin receptor type 1 |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | Phase 1 |
Approved indications
- Insomnia
Common side effects
- Somnolence
- Headache
- Fatigue
- Nasopharyngitis
- headache
- somnolence
- Upper respiratory tract infection
- Dizziness
- Constipation
- Insomnia
- nasopharnygitis
- Delirium
Key clinical trials
- Sleep Trial to Prevent Alzheimer's Disease (Phase 2)
- Efficacy of Suvorexant in Patients With Effectively Treated Restless Legs Syndrome and Persistent Chronic Insomnia: A Randomized Placebo-Controlled Crossover Trial (Phase 4)
- Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related Drinking (Phase 2)
- Influence of Orexin Antagonism on Motivation for Cocaine (EARLY/Phase 1)
- The Role of Orexin in Human Panic Disorder (Phase 4)
- Effects of the Orexin Receptor Antagonist Suvorexant on Sleep Architecture and Delirium in the Intensive Care Unit: A Multi-Centric Randomized Controlled Trial (Phase 4)
- Influence of Orexin Antagonism on Motivation for Alcohol (EARLY/Phase 1)
- Efficacy of Suvorexant to Improve Postoperative Sleep and Reduce Delirium Severity in Older Surgical Patients: A Double-blinded, Randomized, Placebo-controlled Trial (Phase 2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |